FDA closes review of Novartis data integrity scandal with no penalty

FDA closes review of Novartis data integrity scandal with no penalty

STAT Plus: FDA closes review of Novartis data integrity scandal without punishing the drug maker

By ED SILVERMAN

RUBY WALLAU FOR STAT

After its review, the FDA decided it found significant and objectionable conditions, but these did not warrant further regulatory action.

READ MORE